Damage-associated molecular pattern-activated neutrophil extracellular trap exacerbates sterile inflammatory liver injury
Can compounded semaglutide cause serious health issues
A 2023 review in the Journal of Clinical Endocrinology & Metabolism highlighted that GLP-1s can delay gastric emptying significantly, especially at higher doses or early in treatment.44 Another study found that just over 5% of patients experience gastroparesis and it was more likely when using liraglutide or dulaglutide when compared with semaglutide.45 A 2024 cross-sectional analysis in Pharmaceuticals examined the GI side effects of semaglutide, dulaglutide, liraglutide, and exenatide in over 10,000 adults with T2DM or obesity from the National Institutes of Health All of Us cohort.45 They found that abdominal pain was the most frequently reported GI issue (57.6%), followed by constipation, diarrhea, nausea/vomiting, GI bleeding, gastroparesis, and pancreatitis
Although the ELIXA studythe only CVD outcome trial of GLP-1 RAs published to datereported a neutral cardiovascular effect of lixisenatide, the potential cardiovascular benefits of GLP-1 RAs should not be overlooked, because high-risk subjects with established CVD were recruited in this study to delineate its cardiovascular safety within a short-term period
